Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Toshiya Abe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2148-4852; OpenAlex author ID A5012986870. Sources: OpenAlex.

Their work

Papers
39 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
152
Papers, trials and grants by year

2016: 1 paper · 2017: 6 papers · 2018: 4 papers · 2019: 2 papers · 2020: 5 papers · 2021: none · 2022: 5 papers · 2023: 5 papers · 2024: 4 papers · 2025: 4 papers · 2026: 3 papers

Papers 39

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.surg.2026.110423↗
  3. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  4. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  5. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. Co-author DOI 10.1007/s00432-025-06095-z↗
  6. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.108958↗
  7. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  8. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  9. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  10. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Co-author DOI 10.1186/s13046-024-03060-5↗
  11. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  12. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  13. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). First author DOI 10.1007/s00464-023-10438-7↗
  14. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-023-05591-2↗
  15. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Co-author DOI 10.1111/cas.15901↗
  16. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection. Co-author DOI 10.1245/s10434-023-13936-z↗
  17. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Co-author DOI 10.1002/ijc.33883↗
  18. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s12672-021-00462-1↗
  19. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2020.11.006↗
  20. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2021.10.008↗
  21. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  22. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  23. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  24. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. First author DOI 10.1186/s40792-020-00924-8↗
  25. Correction to: Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. First author DOI 10.1186/s40792-020-01070-x↗
  26. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  27. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  28. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Co-author DOI 10.3892/ijo.2019.4812↗
  29. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. Co-author DOI 10.1016/j.canlet.2017.10.010↗
  30. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.03.031↗
  31. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  32. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6761-6↗
  33. Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2017.08.009↗
  34. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.10.035↗
  35. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
  36. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancr… Co-author DOI 10.18632/oncotarget.15430↗
  37. Cancer-associated peritoneal mesothelial cells lead the formation of pancreatic cancer peritoneal dissemination. Co-author DOI 10.3892/ijo.2016.3829↗
  38. Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients. Co-author DOI 10.3892/ol.2017.6549↗
  39. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sid… Co-author DOI 10.1007/s00268-016-3526-x↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 29 shared papers, 2017–2026 · strength 3.84
  2. Naoki Ikenaga · 15 shared papers, 2022–2026 · strength 2.64
  3. Kenoki Ohuchida · 23 shared papers, 2016–2026 · strength 2.59
  4. Noboru Ideno · 12 shared papers, 2022–2026 · strength 2.13
  5. Masafumi Nakamura · 17 shared papers, 2017–2026 · strength 2.11
  6. Yoshinao Oda · 17 shared papers, 2016–2026 · strength 2.05
  7. Chika Iwamoto · 14 shared papers, 2017–2025 · strength 1.73
  8. Takao Ohtsuka · 15 shared papers, 2016–2026 · strength 1.29
  9. Masafumi Nakamura · 10 shared papers, 2016–2025 · strength 1.17
  10. Koki Oyama · 6 shared papers, 2023–2025 · strength 1.04
  11. Yoshihiro Miyasaka · 14 shared papers, 2016–2025 · strength 1.01
  12. Tomohiko Shinkawa · 6 shared papers, 2020–2025 · strength 0.92
  13. Kazuhiro Koikawa · 11 shared papers, 2017–2024 · strength 0.86
  14. Chikanori Tsutsumi · 5 shared papers, 2020–2025 · strength 0.80
  15. Masataka Hayashi · 5 shared papers, 2023–2024 · strength 0.79
  16. Nao Fujimori · 4 shared papers, 2022–2025 · strength 0.71
  17. Kousei Ishigami · 4 shared papers, 2022–2025 · strength 0.70
  18. So Nakamura · 4 shared papers, 2023–2024 · strength 0.69
  19. Shin Kibe · 8 shared papers, 2017–2023 · strength 0.66
  20. Michael Goggins · 6 shared papers, 2018–2022 · strength 0.64
  21. Haizhen Luo · 4 shared papers, 2023–2024 · strength 0.63
  22. Pingshan Zhong · 4 shared papers, 2023–2024 · strength 0.63
  23. Koji Shindo · 6 shared papers, 2018–2024 · strength 0.61
  24. Hideya Onishi · 3 shared papers, 2024–2026 · strength 0.61
  25. Sho Endo · 10 shared papers, 2017–2019 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.